Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.36 USD
-0.11 (-4.45%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $2.35 -0.01 (-0.42%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
ESPR 2.36 -0.11(-4.45%)
Will ESPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
Other News for ESPR
Optimizing Cash Flow and Market Potential: A Buy Rating for Esperion
What You Missed On Wall Street This Morning
Esperion’s Strategic Financial Moves and Regulatory Successes Prompt a Buy Rating
Fly Intel: Pre-market Movers
Esperion Secures Funding and Clears Debt through Royalty Deal